330 related articles for article (PubMed ID: 38222069)
21. Mesenchymal stem cells pretreated with platelet-rich plasma modulate doxorubicin-induced cardiotoxicity.
Zaki SM; Algaleel WA; Imam RA; Abdelmoaty MM
Hum Exp Toxicol; 2019 Jul; 38(7):857-874. PubMed ID: 30991846
[TBL] [Abstract][Full Text] [Related]
22. VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection.
Räsänen M; Degerman J; Nissinen TA; Miinalainen I; Kerkelä R; Siltanen A; Backman JT; Mervaala E; Hulmi JJ; Kivelä R; Alitalo K
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13144-13149. PubMed ID: 27799559
[TBL] [Abstract][Full Text] [Related]
23. Neonatal murine engineered cardiac tissue toxicology model: Impact of dexrazoxane on doxorubicin induced injury.
Zhen J; Yu H; Ji H; Cai L; Leng J; Keller BB
Life Sci; 2019 Dec; 239():117070. PubMed ID: 31751580
[TBL] [Abstract][Full Text] [Related]
24. A Versatile PDA(DOX) Nanoplatform for Chemo-Photothermal Synergistic Therapy against Breast Cancer and Attenuated Doxorubicin-Induced Cardiotoxicity.
Geng S; Feng Q; Wang C; Li Y; Qin J; Hou M; Zhou J; Pan X; Xu F; Fang B; Wang K; Yu Z
J Nanobiotechnology; 2023 Sep; 21(1):338. PubMed ID: 37735669
[TBL] [Abstract][Full Text] [Related]
25. Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity.
Liu H; Wang H; Xiang D; Guo W
Mini Rev Med Chem; 2017; 17(1):44-50. PubMed ID: 27337969
[TBL] [Abstract][Full Text] [Related]
26. β-Caryophyllene, a natural bicyclic sesquiterpene attenuates doxorubicin-induced chronic cardiotoxicity via activation of myocardial cannabinoid type-2 (CB
Meeran MFN; Al Taee H; Azimullah S; Tariq S; Adeghate E; Ojha S
Chem Biol Interact; 2019 May; 304():158-167. PubMed ID: 30836069
[TBL] [Abstract][Full Text] [Related]
27. Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review.
Fojtu M; Gumulec J; Stracina T; Raudenska M; Skotakova A; Vaculovicova M; Adam V; Babula P; Novakova M; Masarik M
Curr Drug Metab; 2017; 18(3):237-263. PubMed ID: 28059036
[TBL] [Abstract][Full Text] [Related]
28. Alpha-Lipoic Acid Protects Against Doxorubicin-Induced Cardiotoxicity by Regulating Pyruvate Dehydrogenase Kinase 4.
Gong F; Jin J; Li H; Mao H
Cardiovasc Toxicol; 2022 Nov; 22(10-11):879-891. PubMed ID: 35930219
[TBL] [Abstract][Full Text] [Related]
29. Mode of treatment governs curcumin response on doxorubicin-induced toxicity in cardiomyoblasts.
Jain A; Rani V
Mol Cell Biochem; 2018 May; 442(1-2):81-96. PubMed ID: 28929270
[TBL] [Abstract][Full Text] [Related]
30. Recent progress in doxorubicin-induced cardiotoxicity and protective potential of natural products.
Yu J; Wang C; Kong Q; Wu X; Lu JJ; Chen X
Phytomedicine; 2018 Feb; 40():125-139. PubMed ID: 29496165
[TBL] [Abstract][Full Text] [Related]
31. The Protective Effect of Natural Compounds on Doxorubicin-Induced Cardiotoxicity via Nicotinamide Adenine Dinucleotide Phosphate Oxidase Inhibition.
Yousefian M; Hosseinzadeh H; Hayes AW; Hadizadeh F; Karimi G
J Pharm Pharmacol; 2022 Mar; 74(3):351-359. PubMed ID: 34562089
[TBL] [Abstract][Full Text] [Related]
32. Alternative approach for mitigation of doxorubicin-induced cardiotoxicity using herbal agents.
Khan MA; Singh M; Khan MS; Ahmad W; Najmi AK; Ahmad S
Curr Clin Pharmacol; 2014; 9(3):288-97. PubMed ID: 23342982
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic Targets for DOX-Induced Cardiomyopathy: Role of Apoptosis vs. Ferroptosis.
Kitakata H; Endo J; Ikura H; Moriyama H; Shirakawa K; Katsumata Y; Sano M
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163335
[TBL] [Abstract][Full Text] [Related]
34. Chemical Architecture of Block Copolymers Differentially Abrogate Cardiotoxicity and Maintain the Anticancer Efficacy of Doxorubicin.
Abdullah CS; Ray P; Alam S; Kale N; Aishwarya R; Morshed M; Dutta D; Hudziak C; Banerjee SK; Mallik S; Banerjee S; Bhuiyan MS; Quadir M
Mol Pharm; 2020 Dec; 17(12):4676-4690. PubMed ID: 33151075
[TBL] [Abstract][Full Text] [Related]
35. Involvement of Abnormal Gut Microbiota Composition and Function in Doxorubicin-Induced Cardiotoxicity.
Huang J; Wei S; Jiang C; Xiao Z; Liu J; Peng W; Zhang B; Li W
Front Cell Infect Microbiol; 2022; 12():808837. PubMed ID: 35281446
[TBL] [Abstract][Full Text] [Related]
36. Potential targets for intervention against doxorubicin-induced cardiotoxicity based on genetic studies: a systematic review of the literature.
Chen Y; Huang T; Shi W; Fang J; Deng H; Cui G
J Mol Cell Cardiol; 2020 Jan; 138():88-98. PubMed ID: 31751567
[TBL] [Abstract][Full Text] [Related]
37. Dapagliflozin suppresses ER stress and protects doxorubicin-induced cardiotoxicity in breast cancer patients.
Chang WT; Lin YW; Ho CH; Chen ZC; Liu PY; Shih JY
Arch Toxicol; 2021 Feb; 95(2):659-671. PubMed ID: 33211168
[TBL] [Abstract][Full Text] [Related]
38. Role of acetylation in doxorubicin-induced cardiotoxicity.
Li D; Yang Y; Wang S; He X; Liu M; Bai B; Tian C; Sun R; Yu T; Chu X
Redox Biol; 2021 Oct; 46():102089. PubMed ID: 34364220
[TBL] [Abstract][Full Text] [Related]
39. Toxicity of Doxorubicin (Dox) to different experimental organ systems.
Pugazhendhi A; Edison TNJI; Velmurugan BK; Jacob JA; Karuppusamy I
Life Sci; 2018 May; 200():26-30. PubMed ID: 29534993
[TBL] [Abstract][Full Text] [Related]
40. The interplay between genetic background and sexual dimorphism of doxorubicin-induced cardiotoxicity.
Zordoky BN; Radin MJ; Heller L; Tobias A; Matise I; Apple FS; McCune SA; Sharkey LC
Cardiooncology; 2016; 2():4. PubMed ID: 28758028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
